T0	Interventions 26 44	placebo-controlled
T1	Interventions 109 122	dexamethasone
T2	Interventions 135 166	following adjuvant chemotherapy
T3	Interventions 288 315	after adjuvant chemotherapy
T4	Interventions 349 370	receive dexamethasone
T5	Interventions 470 492	receiving chemotherapy
T6	Interventions 528 557	with dexamethasone or placebo
T7	Interventions 740 758	oral dexamethasone
T8	Interventions 789 803	versus placebo
T9	Interventions 878 936	intravenous granisetron and dexamethasone pre-chemotherapy
T10	Interventions 941 957	oral granisetron
T11	Interventions 1140 1189	received fluorouracil/epirubicin/cyclophosphamide
T12	Interventions 1197 1234	received doxorubicin/cyclophosphamide
T13	Interventions 1340 1357	preferred placebo
T14	Interventions 1406 1439	35-58Â %) preferred dexamethasone;
T15	Interventions 1609 1640	patients received dexamethasone
T16	Interventions 1786 1821	regardless of whether dexamethasone
T17	Interventions 1833 1856	was used after adjuvant